Takara Bio Inc (4974):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Takara Bio Inc (4974) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7493
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It offers clinical development of gene therapies for cancer treatment. Takara develops and commercializes medical technologies such as cell and gene therapies for cancer and AIDS. The company also develops original research reagents, scientific instruments, and contracted research services that utilize new genetic and cell engineering technologies. It supports biotechnology research by offering basic research and drug discovery and development services. Takara is headquartered in Kusatsu, Japan.

Takara Bio Inc (4974) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Takara Bio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Takara Bio Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Takara Bio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Takara Bio Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Takara Bio Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Takara Bio Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Rubicon Genomics Raises USD2 Million in Venture Financing 10
Partnerships 11
Rubicon Genomics Enters Into Licensing Agreement With University Of Michigan 11
WaferGen Bio-systems Enters into Distribution Agreement with Takara Bio 12
Takara Bio Enters into Agreement with Integrated DNA Technologies 13
WaferGen Biosystems Enters into Research Agreement with Women’s College Research Institute 14
Rubicon Genomics Enters Into Distribution Agreement With GenoMax Technologies For DNA Library Prep Kits 15
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 16
WaferGen Biosystems Enters Into Co-Marketing Agreement With Qiagen 17
Takara Bio Enters Into Co-Marketing Agreement With Pathogenica For HAI Sequencing Service 18
WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies 19
Fluxion Bioscience Enters Into Technology Integration Agreement With Rubicon Genomics 20
Rubicon Genomics Enters Into Technology Integration Agreement With Kreatech Diagnostics 21
Takara Bio Enters Into Licensing Agreement With InVivoScribe Technologies For FLT3-ITD 22
Equity Offering 23
WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 23
Takara Bio Raises USD112 Million in Public Offering Of Common Stock 24
Acquisition 25
Takara Bio Acquires WaferGen Bio-Systems 25
Takara Bio Acquires Rubicon Genomics for USD75 Million 27
Takara Bio Inc – Key Competitors 28
Takara Bio Inc – Key Employees 29
Takara Bio Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Joint Venture 31
Recent Developments 32
Financial Announcements 32
Nov 28, 2017: Takara Bio: Consolidated Financial Statements for the Second Quarter Ended September 30, 2017 32
Legal and Regulatory 34
Oct 15, 2018: CAP-LAP certification of clinical testing laboratory for Takara Bio’s cancer genetic testing in Osaka University Hospital 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Takara Bio Inc, Medical Equipment, Key Facts, 2018 2
Takara Bio Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Takara Bio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Takara Bio Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Takara Bio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Takara Bio Inc, Deals By Market, 2012 to YTD 2018 8
Takara Bio Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Rubicon Genomics Raises USD2 Million in Venture Financing 10
Rubicon Genomics Enters Into Licensing Agreement With University Of Michigan 11
WaferGen Bio-systems Enters into Distribution Agreement with Takara Bio 12
Takara Bio Enters into Agreement with Integrated DNA Technologies 13
WaferGen Biosystems Enters into Research Agreement with Women's College Research Institute 14
Rubicon Genomics Enters Into Distribution Agreement With GenoMax Technologies For DNA Library Prep Kits 15
Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 16
WaferGen Biosystems Enters Into Co-Marketing Agreement With Qiagen 17
Takara Bio Enters Into Co-Marketing Agreement With Pathogenica For HAI Sequencing Service 18
WaferGen Biosystems Enters Into Agreement With Integrated DNA Technologies 19
Fluxion Bioscience Enters Into Technology Integration Agreement With Rubicon Genomics 20
Rubicon Genomics Enters Into Technology Integration Agreement With Kreatech Diagnostics 21
Takara Bio Enters Into Licensing Agreement With InVivoScribe Technologies For FLT3-ITD 22
WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 23
Takara Bio Raises USD112 Million in Public Offering Of Common Stock 24
Takara Bio Acquires WaferGen Bio-Systems 25
Takara Bio Acquires Rubicon Genomics for USD75 Million 27
Takara Bio Inc, Key Competitors 28
Takara Bio Inc, Key Employees 29
Takara Bio Inc, Other Locations 30
Takara Bio Inc, Subsidiaries 30
Takara Bio Inc, Joint Venture 31

List of Figures
Takara Bio Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Takara Bio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Takara Bio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Takara Bio Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Takara Bio Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Takara Bio Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Takara Bio Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Takara Bio Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Takara Bio Inc (4974):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Electricite de France SA (EDF)-石油・ガス分野:企業M&A・提携分析
    Summary Electricite de France S.A. (EDF) is a state-owned integrated energy company that generates, transmits, distributes and sells electricity; supplies natural gas; and offers energy services such as district heating, thermal energy services and other services. The group generates electricity fro …
  • Hindustan Unilever Ltd (HINDUNILVR):企業の財務・戦略的SWOT分析
    Hindustan Unilever Ltd (HINDUNILVR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Butterfield Private Banking:企業の戦略・SWOT・財務情報
    Butterfield Private Banking - Strategy, SWOT and Corporate Finance Report Summary Butterfield Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Allegra Orthopaedics Ltd (AMT)-医療機器分野:企業M&A・提携分析
    Summary Allegra Orthopaedics Ltd (Allegra), develops, manufactures and sells prosthetic implants and related orthopedic medical devices. Its major products include adult and adolescent clavicle fixation system and pin; shoulder implants; proximal humeral plates; trauma distal radial plates and syste …
  • RCL Foods Ltd. (RCL):企業の財務・戦略的SWOT分析
    RCL Foods Ltd. (RCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Motor Oil (Hellas) Corinth Refineries SA (MOH):企業の財務・戦略的SWOT分析
    Motor Oil (Hellas) Corinth Refineries SA (MOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Bracco SpA:企業の戦略的SWOT分析
    Bracco SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Molecular Partners AG (MOLN):製薬・医療:M&Aディール及び事業提携情報
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet …
  • Mologen AG:企業のM&A・事業提携・投資動向
    Mologen AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mologen AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • PCI Biotech Holding ASA (PCIB):企業の財務・戦略的SWOT分析
    Summary PCI Biotech Holding ASA (PCI Biotech) is a biopharmaceutical company that focus on development and commercialisation of novel therapies for the treatment of cancer. The company develops therapeutic products based on its proprietary photochemical internalisation technology. Its lead product c …
  • Renk AG (ZAR):企業の財務・戦略的SWOT分析
    Renk AG (ZAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Dangote Cement Plc:企業の戦略・SWOT・財務情報
    Dangote Cement Plc - Strategy, SWOT and Corporate Finance Report Summary Dangote Cement Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Brookfield Infrastructure Partners LP:企業のM&A・事業提携・投資動向
    Brookfield Infrastructure Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brookfield Infrastructure Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Power Assets Holdings Limited:企業の戦略・SWOT・財務分析
    Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Power Assets Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Implanet SA (IMPL):医療機器:M&Aディール及び事業提携情報
    Summary Implanet SA (Implanet) is a medical device company that designs, manufactures and markets orthopaedic products. The company offers spine, knee and arthroscopy products. Its spine products are used for the treatment of spinal disorders and spinal fusion surgery. Implanet offers resorbable anc …
  • Grupo Televisa S.A.B.:企業の戦略・SWOT・財務分析
    Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report Summary Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Royal Dutch Shell Plc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Royal Dutch Shell Plc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Royal Dutch Shell Plc (Shell) is an integrated oil and gas company. The company explores for and produces oil and gas from conventional fields and sources such as tight rock, shale and coal for …
  • Diagnostics For All Inc:企業の製品パイプライン分析2018
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • Dean Foods Co:戦略・SWOT・企業財務分析
    Dean Foods Co - Strategy, SWOT and Corporate Finance Report Summary Dean Foods Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Rosenergoatom Concern:電力:M&Aディール及び事業提携情報
    Summary Rosenergoatom Concern (Rosenergoatom) is a subsidiary of Atomenergoprom, which is electric power generation company, mainly supplying electrical and thermal energy in Russia. The company’s major activities include design, construction, operation and decommissioning of nuclear power plants. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆